Once-daily LABA/ICS combined inhalers versus inhaled long-acting beta2-agonists for people with chronic obstructive pulmonary disease (COPD) Academic Article

abstract

  • This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the effectiveness and safety of once-daily LABA/ICS in a combined inhaler versus once/twice-daily LABA for the treatment of COPD.

publication date

  • 2016-2-29

edition

  • 2016

keywords

  • Chronic Obstructive Pulmonary Disease
  • Nebulizers and Vaporizers
  • Safety